Maintenance therapies for non small cell lung cancer

Frontiers in Oncology

Volumn 4 JUL, Issue , 2014, Pages

  Blais, Normand ^a   Kassouf, Elie ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEMCITABINE; NAVELBINE; PACLITAXEL; PEMETREXED;

CANCER CHEMOTHERAPY; CYTOTOXICITY; GENE MUTATION; HUMAN; LUNG NON SMALL CELL CANCER; MAINTENANCE CHEMOTHERAPY; NONHUMAN; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SHORT SURVEY; TREATMENT PLANNING;

EID: 84907312963     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00213     Document Type: Short Survey

References (21)

1. National Comprehensive Cancer Network (2014) Non-small cell lung cancer (version 3.2014). Available: http://www.nccn.org/professionals/physician_gls/ Accessed 4 April 2014
2. Park JO, Kim SW, Ahn JS, et al.: Phase III trial of two versus four additional cycles in patients who are non progressive after two cycles of platinum-based chemotherapy in non small-cell lung cancer. J Clin Oncol 25 (33): 5233-9, 2007.
3. Soon YY, Stockler MR, Askie LM, Boyer MJ. Duration of chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized trials. J Clin Oncol. 2009; 27:3277-83.
4. Socinski MA, Schell MJ, Peterman A, et al. Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced IIIB/IV non-small-cell lung cancer. J Clin Oncol 2002; 20:1335-1343.
5. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355:2542-50
6. Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009; 373:1525-31
7. Brodowicz T, Krzakowski M, Zwitter M, Tzekova V, Ramlau R, Ghilezan N, et al. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial. Lung Cancer 2006; 52:155-63
8. Perol, M., Chouaid, C., Perol, D., Barlesi, F., Gervais, R., Westeel, V. et al. (2012) Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin gemcitabine induction chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 30: 3516-3524
9. Belani CP, Waterhouse DM, Ghazal H, Ramalingam SS, Bordoni R, Greenberg R, et al. Phase III study of maintenance gemcitabine (G) and best supportive care (BSC) versus BSC, following standard combination therapy with gemcitabine-carboplatin (G-Cb) for patients with advanced nonsmall cell lung cancer (NSCLC). J Clin Oncol 2010; 28(15 Suppl):7506
10. Paz-Ares L, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomized controlled trial. Lancet Oncol 2012; 13:247-55.
11. Patel JD, Hensing TA, Rademaker A, Hart EM, Blum MG, Milton DT, et al. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. J Clin Oncol 2009; 27:3284-9
12. Barlesi, F., De Castro, J., Dvornichenko, V., Kim, J., Pazzola, A., Rittmeyer, A. et al. AVAPERL (MO22089): final efficacy outcomes for patients with advanced non-squamous non small cell lung cancer randomized to continuation maintenance with bevacizumab (Bev) or Bev + pemetrexed (Pem) after first-line Bev-cisplatin-Pem treatment. Eur J Cancer (Oxford) 2011 47: 16.
13. Patel, J., Socinski M, Garon E., Reynolds C., Spigel D., Olsen M. et al. PointBreak: A Randomized Phase III Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non-Small-Cell Lung Cancer JCO October 21, 2013 JCO.2012.47.9626
14. Fidias PM, Dakhil SR, Lyss AP, Loesch DM, Waterhouse DM, Bromund JL, et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2009; 27:591-8
15. Ciuleanu T, Brodowicz T, Zielinski C, Kim JH, Krzakowski M, Laack E, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomized, double-blind, phase 3 study. Lancet 2009; 374:1432-40
16. Sheperd F, Pereira JR, Ciuleanu T, Tan E H, Hirsh V, Thongprasert S et al. Erlotinib in Previously Treated Non-Small-Cell Lung Cancer. N Engl J Med July 14, 2005; 353:123-132
17. Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczesna A, Juhasz E, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomized, placebocontrolled phase 3 study. Lancet Oncol 2010;11:521-9
18. Johnson B, Kabbinavar F, Fehrenbacher L, Hainsworth J, Kasubhai S et al. ATLAS: Randomized, Double-Blind, Placebo-Controlled, Phase IIIB Trial Comparing Bevacizumab Therapy With or Without Erlotinib, After Completion of Chemotherapy, With Bevacizumab for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer JCO October 7, 2013 JCO.2012.47.3983
19. Gaafar RM, Surmont VF, Scagliotti GV, Van Klaveren RJ, Papamichael D, Welch JJ, Hasan B, Torri V, Van Meerbeeck JP; A double-blind, randomized, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03) Euro J Cancer 2011 Oct;47(15):2331-40
20. Zhang L, Shenglin M, Song X, et al. Efficacy, tolerability, and biomarker analyses from a phase III, randomized, placebo-controlled, parallel group study of gefitinib as maintenance therapy in patients with locally advanced or metastatic NSCLC J Clin Oncol [Abstract LBA7511] May 2011 vol. 29
21. Takeda K, Hida T, Sato T, et al. Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer: WJTOG0203; J Clin Oncol 2010; 28:753-60.